Back to search results

Study of BMS-986507 Combinations for Advanced Solid Tumors

This study is testing different combinations of a drug called BMS-986507 with other approved cancer medicines like Osimertinib, Pembrolizumab, Nivolumab, and Pumitamig. It aims to see how safe these combinations are, how well your body handles them (tolerability), how much drug stays in your system, and if they show early signs of working against advanced solid tumors, including lung and breast cancer. You might be able to join if you are an adult with advanced solid tumors, have measurable disease, a good general health status (ECOG Performance Status of 0 or 1), and a life expectancy of at least 3 months. The study will mainly look at side effects to determine success. This study is currently unclear about its recruitment status and plans to enroll 416 participants.

Study design
This is an interventional study planning to enroll 416 adult participants. It is testing different drug combinations.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06618287

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~416 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:BMS-986507OsimertinibPembrolizumabNivolumabPumitamig

At a glance

Recruiting sites
43 of 66 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with adverse events (AEs)
Measured over Up to 3 years
+5 more outcomes measured

Conditions

Lung Cancer
Breast Cancer

Explore related trials

Breast CarcinomaLung Non-Small Cell CarcinomaSolid NeoplasmSoluble Epidermal Growth Factor Receptor

Where it's being run

66 sites across 48 states
Spain6
Oregon3
Ontario3
Quebec3
Santiago Metropolitan3
Ohio2
France2
Barcelona [Barcelona]2

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of the first dose.
Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed
Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.
Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.
Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen.
Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.

Exclusion

Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
Participants with known mutations in EGFR will be excluded (Group A,B and E).
Participants must not have a history of serious recurrent infections.
Participants must not have a history of severe heart disease.

What this trial measures

  • Number of participants with adverse events (AEs)Up to 3 years
  • Number of participants with serious adverse events (SAEs)Up to 3 years
  • Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteraUp to 3 years
  • Number of participants with AEs leading to discontinuationUp to 3 years
  • Number of participants with AEs leading to deathUp to 3 years
  • Number of DLTs that occur during the DLT evaluation periodUp to 3 weeks